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p300 Interacts with the Nuclear Proto-Oncoprotein
SYT as Part of the Active Control
of Cell Adhesion
Total CBP plus p300 gene dosage is important in
embryonic development (Yao et al., 1998). Nullizygosity
at either locus or double heterozygosity causes embry-
onic lethality. Furthermore, p300 or CBP heterozygosity
can lead to significant mouse embryonic lethality, im-
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plying that heterozygosity at either locus translates into
significant haploinsufficiency. The latter effect can be
linked to a cancer-prone state. Specifically, patients with
Summary one wild-type and one mutant germ line copy of CBP
develop a rare, multisystem disorder, Rubinstein Taybi
Complexes containing p300, but not CBP, and the nu- syndrome, among whose many elements is a height-
clear proto-oncoprotein SYT were detected in conflu- ened cancer risk (Giles et al., 1998). Indeed, a recently
ent cultures of G1-arrested cells but not in sparse cells developed CBP1/2 mouse model is characterized by
or during S or G2. SYT sequences constitute the N-ter- marked hematologic neoplasm development (Kung et
minal segment of a fusion oncogene product, SYT- al., 2000). By contrast, p300 heterozygous animals were
SSX, routinely detected in synovial sarcoma, an ag- disease free, indicating that p300 and CBP perform dis-
tinct as well as common functions.gressive human tumor. SYT/p300 complex formation
Here, we report an additional and heretofore unex-promotes cell adhesion to a fibronectin matrix, as re-
pected role for p300 in the regulation of cell adhesion,flected by compromise of this process in cells ex-
which appears to be mediated by p300 association withpressing SYT dl mutants that retain p300 binding activ-
a proto-oncoprotein, SYT (synovial sarcoma transloca-ity and in the primary fibroblasts of p300 but not CBP
tion). Adhesion of a cell to its extracellular matrix andheterozygous null mice. The mechanism linking the
its ability to communicate with its environment are fun-action of SYT/p300 complexes to adhesion function
damental properties integral to proliferation control, cel-is, at least in part, transcription activation–indepen-
lular homeostasis, and organ development (Ruoslahti,dent and results in proper activation of b1 integrin, a
1999). By contrast, deregulation of cell adhesion is asso-major adhesion receptor.
ciated with cell cycle arrest and apoptosis, in some
cases (Frisch and Ruoslahti, 1997), and tumor develop-
Introduction ment and invasiveness in others (Keely et al., 1998). Cell
adhesion is the consequence of complex and incom-
p300/CBP complexes are large nuclear proteins that pletely understood networks of signaling events that
participate in the control of organ development and the emanate from the cell surface and are transmitted to the
regulation of numerous homeostatic processes, such cytoplasm, where they affect cytoskeletal organization,
as cell proliferation, differentiation, and apoptosis (Con- cell shape, and motility (Burridge and Chrzanowska-
dorelli and Giordano, 1997; Giles et al., 1998; Shi and Wodnicka, 1996). Recent evidence implies that some of
Mello, 1998). Experiments on the transforming behavior these cytoplasmic pathways lead to discrete, nuclear
of small DNA tumor viral oncoproteins indicate that com- signal transduction events (Boudreau and Jones, 1999).
plexes of the latter with p300 and/or CBP translate into The latter, in turn, affect expression of genes important
major losses of cell growth control. These include forced for the enaction of cellular responses to changes in
emergence from G0, loss of contact inhibition of cell adhesion and/or motility. By contrast, a role for specific
growth, and blockade of major pathways of cellular dif- nuclear events in the maintenance of a normally adhe-
ferentiation (Bayley and Mymryk, 1994). In effect, p300/ sive state has not been demonstrated, although there
CBP complexes appear to suppress neoplastic transfor- are reasons to suspect such a relationship. In this re-
mation. In this regard, recent evidence points to hemato- gard, p300/SYT complexes appear to be nuclear.
poietic tumor suppression activity by endogenous CBP
(Giles et al., 1998; Kung et al., 2000) and the existence Results
of biallelic mutations in p300 in certain common solid
tumors (Gayther et al., 2000). A 50-kDa Polypeptide Associates with p300/CBP
Little is known about how p300/CBP complexes con- in Contact-Inhibited Cells
tribute to transformation suppression. However, it is In a search for previously undefined proteins that associ-
suspected that p300/CBP regulates certain biological ate with p300/CBP in a proliferation-dependent manner,
events through the integration of networks of signaling we used mAbs that react with different regions of p300/
pathways. This occurs, in part, by their regulated associ- CBP to immunoprecipitate endogenous p300/CBP com-
ation with key nuclear proteins specific to such path- plexes from lysates of synchronized CV-1 cells (African
ways, which leads to transcriptional coactivation of se- monkey kidney cells). Immunoprecipitates (IPs) of ex-
lected genes (Shikama et al., 1997) and acetylation tracts of confluent, contact-inhibited G1 cells were com-
(Giordano and Avantaggiati, 1999) and/or regulated deg- pared with those of early S phase cells. Analysis of the
radation of selected protein targets (Grossman et al., relevant IP revealed several coprecipitating polypep-
1998). tides, including a 50-kDa species (p50) present in the
G1 co-IP that was absent from the S phase IP (Figure
1A, cf. lanes 1 and 2 with 3). An irrelevant antibody of* To whom correspondence should be addressed (e-mail: david_
livingston@dfci.harvard.edu). the same isotype as the p300/CBP antibody failed to
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either serum starvation of or DNA damage (10 Gy) to
confluent G1 CV-1 cells, suggesting that the presence
of this complex is not a G1 checkpoint response (data
not shown).
Partial peptide mapping was performed on p300/
CBP–associated p50 from multiple cell types, epithelial
and fibroblast, human and rodent (IMR90, 293, U2-OS,
NIH3T3 [mouse], and MvLu [mink]), all growing as mono-
layers. p50, characterized by a similar basic digestion
pattern, was detected as a p300 and/or CBP binding
protein in all cell lines tested (Figure 1D; data not shown).
It also coprecipitated with p300/CBP in IPs generated
with two different p300/CBP mAbs, each of which reacts
with a unique epitope (AC240 and RW144; data not
shown). Thus, it appears that the p50 primary structure
is well conserved among mammals, as is its ability to
interact with p300 and/or CBP.
p50 Is SYT, a 45-kDa Proto-Oncoprotein
In an effort to identify p50, we purified it using p300
coimmunoprecipitation. After copper staining, the co-
precipitated p50 band was excised and subjected to
microsequencing. The sequence of the dominant peak
in the tryptic peptide profile was GKGEITPAAIQK, which
by database analysis is present in the sequence of SYT,
a known human protein. SYT was originally identified
as the 59 segment of a fusion protein, SYT-SSX, a prod-
uct of chromosomal translocation t(X;18)(p11.2;q11.2)
involving two genes, SYT on chromosome 18 and SSX
on the X chromosome (Clark et al., 1994). This fusion
gene exists in .90% of synovial sarcomas, implyingFigure 1. P50 Associates with p300/CBP in Contact-Inhibited CV-1
that the fusion product is vital to its development. InCells
most SYT-SSX translocations, the eight C-terminal resi-(A) Lysates from 35S-met-labeled, newly confluent (G1; lane 1), long
dues of SYT are lost, and the remaining SYT gene isconfluent (G1; lane 2), and hydroxyurea-arrested (lane 3) cells were
fused in frame to the 39 half of SSX (Crew et al., 1995).immunoprecipitated with the p300/CBP mAb AC240. p50 is indi-
SYT cDNA was cloned by PCR, based on the 59 andcated by an arrowhead.
(B) p50 (arrowhead) coprecipitated with p300/CBP (lane 1) from 39 ends of the published sequence (Clark et al., 1994).
35S-met-labeled, confluent CV-1 cells and failed to reprecipitate with When in vitro transcribed and translated, the product of
AC240 (lane 2). this cDNA comigrated with p300/CBP–associated p50
(C) Ac240 IP of in vivo–labeled cells arrested with hydroxyurea (HU) (Figure 2A, cf. lanes 2 and 3), and their chymotryptic
and released in the presence of nocodazole for 3, 5, and 7 hr. The partial digestion products were indistinguishable (Figure
G1 lane contains a co-IP from confluent G1-arrested cells. Using 2B, cf. lanes 1 and 2).fluorescence-activated cell sorting (FACS) analysis, we found that
Finally, to determine whether it was SYT that copre-92% of the confluent cells were in G1, and z90% of hydroxyurea
cipitated with p300/CBP in the G1 confluent, contact-cells were at G1/S. At 3 hr postrelease, 73% were in S phase, and
inhibited state, we used a specific, affinity-purified poly-63% and 75% were in G2/M at 5 and 7 hr postrelease, respectively.
clonal antibody (B24) raised against newly generated(D) p50 bands, coimmunoprecipitated with AC240 from lysates of
35S-labeled, G1-arrested NIH3T3, CV-1, and IMR90 cells (lanes 1, 2 clonal SYT. The results revealed that p50, which coim-
and 3, respectively), were each excised from the gel and subjected munoprecipitateded with p300/CBP using p300 anti-
to partial V8 protease digest analysis, as described in Experimental body, was successfully re-immunoprecipitated by B24,
Procedures. except when the antibody was preincubated with GST-
SYT (Figure 2C). By contrast, it did re-immunoprecipitate
when the antibody was preincubated with unfused GST.
immunoprecipitate p300/CBP or p50 (data not shown). Moreover, in keeping with independent results obtained
Upon boiling a similar IP generated in 500 mM NaCl- upon analysis of metabolically labeled p300/p50 com-
containing buffer, we found that p50, unlike p300/CBP, plexes in confluent versus sparse G1 CV-1 cells (data
failed to reprecipitate with p300/CBP antibody, implying not shown), the endogenous SYT-p300/CBP complex
that it is a p300/CBP–associated protein as opposed to (detected by anti-SYT IP, using B24, and immunoblot-
a cross-reactive one (Figure 1B). ting with p300/CBP antibody) was also observed in con-
Further analysis of confluent G1 versus synchronized fluent and was greatly diminished in sparse cells (Figure
cycling cells was performed, again in search of p300/ 2D, cf. lanes 3 and 12). Thus, complexes of SYT with
CBP-p50 complexes (Figure 1C). The data revealed that p300 and/or CBP accumulate in confluent but not sparse
p50-containing complexes were detected in G1 but that G1 cells. Lack of SYT/p300 complex formation was not
they were difficult to detect at the beginning of S phase associated with a lack of expression of SYT during the
or for up to 7 hr after release from a hydroxyurea block. various cell cycle intervals that were studied, as re-
By 7 hr after hydroxyurea release, the synchronized cul- flected in a Western blot for SYT protein performed
ture was largely composed of G2/M cells. Furthermore, on standardized quantities of the relevant cell extracts
analyzed in Figure 2D (lower panel).the interaction of p50 with p300/CBP persisted after
SYT/p300 Complex and Cell Adhesion
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Figure 2. p50 Is the Proto-Oncoprotein SYT
(A) An SYT IP (B24 antibody; lane 1) and a p300/CBP IP (AC240 antibody; lane 2) from an in vivo–labeled CV-1 extract in G1 were resolved
in an SDS gel adjacent to in vitro–translated SYT (lane 3).
(B) p50 and the in vitro–translated band corresponding to full-length SYT (see arrowheads in Figure 2A) were excised and subjected to partial
chymotrypsin digestion.
(C) An AC240 IP from in vivo–labeled, confluent CV-1 cells (G1) was boiled and precipitated with B24, with B24 preincubated with SYT beads
(B241SYT), or with B24 preincubated with GST beads (B241GST). As described in Figure 1C, the culture was arrested with hydroxyurea (HU)
and then released into the cycle for various times at which it was lysed and immunoprecipitated with Ac240.
(D) (Top) Lysates from confluent G1-arrested CV-1 cells (C), hydroxyurea (HU)- or nocodazole (N)-arrested cells, and sparse G1 cells (SP)
were immunoprecipitated with AC240 (lanes 1, 4, 7, and 10), preimmune serum (lanes 2, 5, 8, and 11), or B24 (lanes 3, 6, 9, and 12). The p300
antibody (AC240) was used for immunoblotting. (Bottom) SYT immunoblot (B24) of matched quantities of lysate from CV-1 cells cultivated
under different conditions.
SYT Is a Nuclear Protein That Specifically E1A plus ras were uniformly unsuccessful. Therefore,
given the selective association of SYT with p300 in con-Associates with p300
p300 and CBP are highly homologous nuclear proteins, tact-inhibited cells, we asked whether SYT/p300 com-
plex formation was an indicator of the state of cell adhe-but in vivo genetic studies reveal that they are not identi-
cal in their repertoire of functional properties (Yao et al., sion to a solid substratum and/or matrix. In this regard,
confluent, contact-inhibited CV-1 cells were detached1998; Kung et al., 2000). To determine whether one,
the other, or both of them interact with SYT in vivo, from a tissue culture dish after brief treatment with
EDTA. They were washed with divalent cation-free saltendogenous SYT was immunoprecipitated from CV-1
cells, and the identity of its p300/CBP coprecipitating solution, resuspended in growth medium, and then al-
lowed to rotate at 378C on a mechanical wheel for in-partner was sought by blotting with p300- and CBP-
specific mAbs. The analysis revealed the presence of creasing time periods to prevent them from reattaching.
At the indicated time points, the abundance of SYT/p300 (Figure 3A, top) but not CBP (Figure 3A, bottom)
in complex with endogenous SYT. In addition, when HA- p300 complexes was compared with that in naive adher-
tagged p300 and MYC-tagged CBP were cotransfected ent cells. The data revealed that complexes were still
into these cells and expressed at adequate levels, an detectable after 15 but not 40 min of suspension (Figure
anti-SYT IP contained HA-p300 but not MYC-CBP (Fig- 4A). By contrast, the abundance of SYT (same figure)
ure 3B). Thus, SYT interacts with p300 but not CBP, and p300 (data not shown) did not change dramatically
underscoring the growing sense that these proteins can during the course of the experiment.
display distinct functions in certain somatic cells (Kawa- To search for a relationship between the presence of
saki et al., 1998; Yao et al., 1998; Yuan et al., 1999). p300/SYT complexes and the state of cell spreading,
To search for the intracellular location of endogenous an adhesion-dependent process, we exposed confluent
SYT, cells were immunostained with the aforementioned CV-1 cells for a brief time to divalent cation-free buffer
affinity-purified SYT antibody (B24). The result was or buffer containing EGTA. Both conditions cause cells
strong nuclear fluorescence, with no signal arising when to round up (Figure 4C) without becoming detached.
preimmune serum was tested (Figure 3C). An HA anti- Subsequent replenishment with normal, serum-con-
body yielded a similar pattern in cells transfected with taining medium allowed the cells to respread normally
HA-SYT. Finally, upon biochemical cell fractionation, (Figure 4C). The effect of these various conditions on the
both total SYT and the SYT/p300 complexes were de- abundance of endogenous SYT/p300 complexes was
tected only in the nuclear fraction (data not shown). analyzed by anti-SYT co-IP and anti-p300 immunoblot.
Thus, like p300, SYT and SYT/p300 complexes appear When compared with adherent cells (Figure 4B, lane 1),
to be primarily nuclear elements. a brief exposure to divalent cation-free salt solution or
EGTA led to cell rounding (Figure 4C) and simultaneous
disappearance of SYT/p300 complexes (Figure 4B,The Endogenous SYT/p300 Interaction Is
lanes 2–4). When the rounded cells were allowed toDynamically Regulated by the State
respread (Figure 4C), SYT/p300 complexes reappearedof Cell Adhesion
(Figure 4B, lanes 5–7). When newly respread cells were re-Efforts to discern an effect of wild-type or mutant SYT
on cell growth, proliferation rate, or transformation by incubated with divalent cation-free solution, cells rounded
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ability to interact with in vitro–translated, full-length SYT
(Figure 5A). The data imply that there are two specific
segments of p300 with affinity for SYT. One contains
the C/H1 and the other the C/H3 domain (Figure 5A,
lanes 1 and 3, and 5 and 6, respectively). By contrast,
under the conditions employed, the C/H2 domain and
its flanking region failed to bind SYT (Figure 5A, lane
4). Therefore, there may be multiple, specific modes of
contact between p300 and SYT.
HA-tagged N- and C-terminal SYT deletion mutants
were created (Figure 5B). When these cDNAs were ex-
pressed at similar levels (data not shown) in U2–0S cells,
mutants lacking at least 43 residues from the extreme
SYT N terminus failed to bind to p300, as defined by anti-
SYT co-IP. By contrast, both small and more extensive
deletions from the C terminus did not affect this interac-
tion (Figure 5B; data not shown).
Effect of SYT Mutants on Cell Adhesion
Given the existence of a relationship between the abun-
dance of SYT/p300 complexes and the state of cell ad-
hesion, we asked whether overproduction of one or
more SYT mutants affects the adhesive state of the
relevant transfected cells. Thus, CV-1 cells were cotrans-
fected with expression vectors encoding GFP and either
HA-tagged wild-type SYT or one of the aforementioned
HA-tagged SYT dl mutants (Figure 5B). Transfected
cells were assayed for their ability to adhere to a fibro-
nectin-coated surface, as compared with a poly-L-lysine
coated one (poly-L-lysine is a nonspecific adhesive sur-
face). Adhesion was measured as the ratio of the num-
Figure 3. SYT Interacts Selectively with p300 and Not CBP ber of GFP-containing cells adherent to standardized
(A) SYT IPs (B24) of extracts from contact-inhibited CV-1 cells were fibronectin monolayers relative to the number adherent
analyzed for coprecipitating p300 (top) or CBP (bottom). The latter to poly-L-lysine coated coverslips after a 30-min in-
proteins were detected by immunoblotting with p300- and CBP- cubation (see Experimental Procedures). All mutants
specific mAbs (RW128 and AC238, respectively). Lane 2 contains tested were expressed at equivalent levels, and all were
an IP generated with preimmune serum (IP-PreImm). Ac240, which localized in the nucleus, as shown by immunofluores-immunoprecipitates both p300 and CBP, was used as a positive
cence (data not shown). When compared with the con-control in both blots.
trol vector, neither wild-type SYT nor the C-terminal dl(B) p300-CHA (HA-tagged) and h-CBP-MH (Myc-tagged) were ex-
mutants (SYT34 and SYT35) affected fibronectin adhe-pressed in U2-OS cells (panel 1, HA immunoblot of lysates of trans-
sion. By contrast, the C-terminal mutants (SYT28 andfected U2-OS cells; panel 3, Myc immunoblot of lysates of trans-
SYT29) inhibited fibronectin adhesion significantly (Fig-fected U2-OS cells). Endogenous SYT was tested for binding to
transfected HA-p300 and/or MYC-CBP by B24 co-IP followed by ure 5B). All transfected cells adhered equivalently to
immunoblotting with anti-HA (panel 2) and anti-Myc (panel 4) anti- poly-L-lysine, and their viability was unaffected by the
bodies. Lysates of cells transfected by the backbone vector were transfection procedure.
analyzed in the first lane of both panels. These data indicate that certain SYT mutants (two
(C) SYT immunostaining of U2-OS cells with B24 for the endogenous C-terminal dl species) exert a dominant negative effect
protein and with anti-HA for transfected HA-SYT. on cell adhesion, implying a normal contribution to this
process by endogenous SYT. Similar results were ob-
tained in NIH3T3 cells (data not shown), indicating thatup again, and p300/SYT complexes again diminished in SYT function may affect cell adhesion in cultured, im-
abundance, reappearing again after subsequent re- mortalized cells of both epithelial and fibroblast, as well
spreading (Figure 4B, lanes 8 and 9, respectively). Reac- as primate and murine origin.
cumulation of SYT/p300 complexes occurred in a time- SYT34 and 35, which were inert in these assays, can-
dependent manner during the period of respreading not bind to p300, suggesting that the expression of dom-
(data not shown). Neither the cellular abundance of SYT inant interfering activity by the relevant mutants requires
or p300 (determined by Western blotting with monospe- stable p300 binding. This, in turn, suggests that the
cific antibodies) nor their nuclear localization (deter- contribution to cell adhesion made by SYT requires its
mined by immunofluorescence) changed during the interaction with p300. In this regard, it is worth noting
course of the experiment (data not shown). Thus, there that SYT28, which lacks the eight C-terminal residues
is a dynamic relationship between SYT/p300 complex of the protein, is the deletion mutation of SYT most
formation and the state of cell adhesion/spreading, commonly detected in the SYT/SSX tumor fusion prod-
which is independent of the abundance of either protein. uct (see Introduction).
Structure–Function Relationships Underlying Effect of p300 Gene Dosage upon Embryonic
the SYT/p300 Interaction Cell Adhesion Properties
To identify the regions of binding between SYT and To assess the putative role of p300 in cell adhesion
control, we performed experiments on embryonic cellsp300, a series of p300 dl mutants were tested for their
SYT/p300 Complex and Cell Adhesion
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Figure 4. Cell Detachment Is Associated with
Dissociation of SYT from p300
(A) B24 co-IP from confluent G1 CV-1 cells
detached with EDTA, then left in suspension
for 0, 15, or 40 min (lanes B2, B3, and B4,
respectively). Lane B1 contains a B24 co-IP
of attached cells, and each lane A contains
an IP performed with preimmune serum at the
time indicated above. p300-specific antibody
was used for immunoblotting. The lower
panel shows a B24 immunoblot of cellular
SYT present in the test cells at the indicated
times.
(B) B24 co-IP of extracts of CV-1 cells that
were allowed to round up on the culture dish
after a 5-min incubation period in HCMF alone
(lane 2) or in HCMF supplemented with 5 mM
EGTA for 5 min (lane 3) or 15 min (lane 4).
Lanes 5, 6, and 7 represent B24 co-IPs from
the rounded cells (in lanes 2, 3 and 4, respec-
tively) that were allowed to respread in com-
plete medium. Lanes 8 and 9 are B24 co-IPs
of newly respread cells (in lane 7) that were
rerounded and then respread, respectively.
Lane 1 shows contact-inhibited/adherent
cells.
(C) From left to right, respectively, rhodamine
phalloidin staining of cultures that had
attached, were then allowed to round up, and
subsequently to respread.
freshly prepared from wild-type E9.5 mouse embryos To determine whether this relationship extends to cell
adhesive properties and, if so, whether the effect isand littermates that were heterozygous null for p300 or
CBP. Previous studies have shown that heterozygosity p300-specific—in keeping with the absence of a CBP
interaction with SYT—we analyzed the adhesive proper-at the p300 locus or CBP locus is accompanied by
haploinsufficiency for certain functions (Giles et al., ties of isogenic, fresh primary embryonic cells (MECs) of
defined genotype (wild type vs. CBP1/2 vs. p3001/2).1998; Yao et al., 1998).
Figure 5. Specific Protein Binding Segments of p300 and SYT and the Effect of Certain SYT dl Mutants on Cell Adhesion
(A) Various GST-p300 proteins were synthesized and tested for binding to in vitro–transcribed, 35S-labeled full-length SYT, as described
(Grossman et al., 1998); lane 1 represents 10% of the in vitro–transcribed SYT input used in the assay. Lanes 1 through 6 contain binding
mixtures bearing the various (GST-)p300 segments reflected in the upper part of the figure. In lane 2, unfused GST was used.
(B) SYT mutants were created as described in Experimental Procedures. (1) indicates detectable binding of SYT and/or one or more of its
dl mutants to p300; (2) indicates lack of binding. CV-1 cells were cotransfected with GFP expression vector plus the backbone vector or an
expression vector encoding wild-type SYT or the indicated SYT mutant. Percentage of adhesion (% adhesion) represents a ratio of the fraction
of green fluorescing cells that adhered to fibronectin relative to the fraction that adhered to a nonspecific control surface (i.e., poly-L-lysine-
coated plates; .90% in all cases). ND, not determined.
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function of these complexes is regulated by differentialTable 1. Adherence Properties of p300 and CBP Heterozygous
modification. Importantly, SYT contains three SH2- andEmbryo Cells
one SH3- consensus motifs (see Figure 5B). With these
Genotype
facts in mind, endogenous SYT IPs (B24) of lysates de-
wt CBP1/2 p3001/2 rived from labeled confluent and sparse CV-1 cells were
boiled and reprecipitated, in parallel, with either B24159 309 159 309 159 309
(Figure 6C, lanes 1 and 4) or a phosphotyrosine-specific
Experiment 1 $99 $99 $99 $99 9 10 mAb (4G10). Using 4G10, a specific polypeptide that
$99 $99 $99 $99 44 68 comigrated with SYT from the same extract was de-
Experiment 2 $99 $99 35
tected, along with two additional, more intense bands
$99 $99 65
(z52 and 58 kDa; Figure 6C, lane 2). These two reprecipi-
The experiments were performed as described in Experimental Pro- tated bands were detected only in the confluent cell
cedures. The data reported here are expressed as percentage of extract and failed to reprecipitate with SYT antibodies,
cells that adhered specifically to fibronectin-coated cover slips and suggesting that they are likely phosphotyrosine-con-
are the product of two independent double-blinded experiments.
taining SYT-associated proteins rather than SYT deriva-wt, wild type.
tives.
There was no hint of SYT tyrosine phosphorylation or
of any putative coprecipitating, p-tyr-containing partner
in sparse cell extracts (Figure 6C, lane 5), although theThese cells were freshly derived from embryos of the
same genetic background (C57BL/6). Homozygous null level of endogenous SYT was similar to that in confluent
cells. These data imply that when SYT/p300 complexescells were not analyzed here because they are severely
defective in proliferation and undergo early growth ar- form in contact-inhibited cells, SYT becomes tyrosine-
phosphorylated and interacts with at least two new part-rest (Yao et al., 1998). The question was whether freshly
explanted, unmanipulated primary cells, taken from ners that are also tyrosine-phosphorylated.
In an effort to detect downstream targets of SYT/p300wild-type E9.5 embryos and from E9.5 embryos lacking
one copy of the CBP or p300 gene, were or were not complexes, we transfected cells with SYT DN mutants
and analyzed the abundance of the primary fibronectindefective in adhesion behavior.
Cells from freshly dissected embryos were assayed receptor, b1 integrin, as well as focal adhesion–asso-
ciated proteins known to be active in promoting cellfor their ability to adhere to fibronectin- coated surfaces,
as described above. Other aliquots of these test cells adhesion. In such cells, which are defective in cell adhe-
sion, there was no detectable change in the level orwere independently genotyped by a second operator.
When the double-blinded genotype and cell adhesion tyrosine phosphorylation profile of b1 integrin, focal ad-
hesion kinase, p130cas, or paxillin (Figure 6D; data notresults were analyzed together, it was apparent that in
comparison with wild-type and CBP1/2 MECs, MECs shown). In contrast, when compared with vector-trans-
fected cells, the extent of b1 integrin receptor activationfrom multiple embryos with a p3001/2 genotype were
overtly and repeatedly defective in adhesion (Table 1). by manganese (Bazzoni et al., 1998) was significantly
inhibited in the presence of either SYT DN mutant (seeThus, it appears that the p300 (as opposed to the CBP)
gene dose has a major effect on cell adhesive properties, Figure 6E for an example of an effect of SYT 29). Activa-
tion was measured by the ability of the receptor to adoptin keeping with the fact that p300 and not CBP is an SYT
binding partner. These findings reinforce the hypothesis an activation-specific conformation that allows it to in-
teract with a specific, anti-b1 integrin mAb (Bazzoni etthat SYT/p300 complexes are active controlling ele-
ments in fibronectin adhesion function. al., 1995). When quantitated by comparison with cells
synthesizing comparable quantities of ectopically ex-
pressed wild-type SYT, there was an z44% reductionInsights into the Mechanism Linking SYT/p300
in 9EG7 reactivity of cells synthesizing SYT 29 and anComplexes to Cell Adhesion Control
z24% reduction in cells synthesizing SYT 28 (Figure 6E;To determine whether the effect of SYT/p300 complex
see also Figure 5B for mutant structures). To control foron cell adhesion is dependent on active transcription,
cell viability and gross integrity, we also analyzed allwe incubated CV-1 cells with enough actinomycin D
cells after plating on a poly-L-lysine surface to which all(5mg/ml for 3 hr) to block transcription effectively. Sub-
adhered with equivalent, high efficiency (.90%). Takensequently we allowed the cells to round up on a culture
together, these results imply that at least one participantdish and then to respread in complete, drug-containing
in the interruption of adhesion by the relevant SYT DNmedium, as described above. Another aliquot was
mutants is inadequate b1 integrin/fibronectin receptortreated similarly in the absence of the drug. As shown
function.in Figure 6A, the cells respread rapidly (i.e., in ,30 min)
and without apparent difficulty with or without the drug,
Discussionand SYT/p300 complexes accumulated normally in the
drug-treated cells (Figure 6B). During the period of drug
exposure, transcription remained arrested in the actino- Indirect evidence, based on studies of E1A and SV40 T
Ag function, implies that p300/CBP actively suppressesmycin-treated cells, as judged by the lack of reappear-
ance of endogenous MYC protein (data not shown). the emergence in cultured cells of multiple neoplastic
characteristics, one of which is loss of contact inhibitionTherefore, in keeping with earlier results of others, it
appears that entering an adherent state occurs in the of cell growth (Dulbecco, 1969; Bayley and Mymryk,
1994). Results presented here reveal an unexpectedabsence of active transcription (Hughes et al., 1997;
Coppolino and Dedhar, 2000). function of p300. It and a known human proto-oncopro-
tein, SYT, interact in the nucleus. Formation of SYT/p300The lack of adhesion dependence on transcription
and the speed with which SYT/p300 complexes re- complexes was confined to G1-arrested, confluent cells,
was absent in sparse G1 cells, and appears to translateformed upon cell spreading led us to speculate that the
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Figure 6. Studies on the Mechanism of SYT/p300 Function
(A) Round 09 shows confluent G1 CV-1 cells; Spread 309, rounded cells respread in complete medium for 30 min; and Spread 3091Act D,
confluent G1 cells, treated for 3 hr with actinomycin D (5 mg/ml) before rounding and respreading in complete, drug-containing medium for
30 min.
(B) B24 (SYT) IP of lysates derived from rounded and respread CV-1 cells cultivated in the presence (ActD) or absence (2) of actinomycin D.
IPs were then Western blotted for p300 (RW128 antibody).
(C) A B24 (SYT) IP of 35S-labeled CV-1 cell extract was boiled and reprecipitated with B24 (SYT) (lanes 1 and 4), with 4G10 (anti-phosphotyrosine)
(lanes 2 and 5), or with PB (preimmune serum) (lane 3).
(D) A 9EG7 (b1 integrin) IP of lysates of CD19-selected CV-1 cells transfected with CD19 expression vector and wild-type SYT (lane S) or the
DN mutants SYT28 and SYT29 (lanes 28 and 29, respectively).
(E) Representative “dim” and “bright” 9EG7-fluorescing cells. An HA-SYT-expressing cell in the upper left panel (green; HA/FITC) was counted
as bright in binding to the corresponding 9EG7 (anti-b1 integrin antibody; red-rhodamine) in the upper right panel. An HA-SYT29-expressing
cell in the lower left panel (green-HA/FITC) was scored as dim for failing to react with b1 integrin antibody 9EG7 in the lower right picture.
Note the surrounding bright untransfected cells in both upper and lower right 9EG7 immunostained cell images. The column on the far right
shows the percentage of b1 integrin receptor activation in CV-1 cells transfected with SYT28 or SYT29 relative to that observed in wild-type
SYT transfected cells (artificially set at 100%).
into proper cell adhesion to a fibronectin matrix. What signals transmitted at the hands of SYT/p300 complex
formation in the nucleus are necessary for this process.seems likely to be a failure to form a sufficient quantity
of these nuclear complexes, as in p3001/2 embryonic This view notwithstanding, the p300/SYT-associated
mechanism is not the only known example of nucleus-cells and in cells synthesizing certain dominant negative
SYT mutants, led to a major defect in cell adhesion/ to-cytoplasm signal transduction of significant biologi-
cal value. Recent work of others points to a role for RB,spreading. Taken together, these results are consistent
with the hypothesis that SYT/p300 complex formation another E1A/SV40 T Ag-associated nuclear protein, in
the control of cell cycle–dependent ras activation inparticipates in the control of contact inhibition of cell
growth, a G1-specific phenomenon, and an adhesion- mammals (Lee et al., 1999). Moreover, there is genetic
evidence for normal communication between RB anddependent process.
Cells bind to an extracellular matrix through integrin ras in the nematode (Lu and Horvitz, 1998). These find-
ings provide a prime example of nuclear regulation ofreceptors. Once achieved, an extensive signaling net-
work is activated. As a result, cytoskeletal reorganiza- the ongoing activity of an extra-nuclear protein engaged
in a vital cellular process—proliferation control.tion occurs, cell adhesion is initiated, and focal adhesion
plaques form and lead to spreading (Schwartz et al., What is not clear is how either SYT/p300 complexes
or RB provides these instructions to their cytoplasmic1995). Mitogenic pathways are also activated and lead
to the regulation of genes important for proliferation targets. There is some circumstantial evidence sug-
gesting that SYT can participate in transcriptional con-control, differentiation, migration, and/or apoptosis
(Zohn et al., 1998). Given the data presented here, one trol events (Brett et al., 1997; dos Santos et al., 1997).
Moreover, SYT associates with BRM (Thaete et al.,can hypothesize that integrin-mediated signals translate
into suppression of monolayer overgrowth mediated, at 1999), a known Swi/SNF participant in chromatin remod-
eling. CBP can interact with SRCAP, yet another Swi/least in part, by de novo generation of p300/SYT nuclear
complexes. In keeping with the view that the signal that SNF family member (Johnston et al., 1999). Finally, p300
and CBP are established transcriptional coactivatorsinitiates complex formation must be adhesion-, extracel-
lular matrix–, and/or cell shape–dependent was the ob- and acetyl transferases, and linkage between transcrip-
tion control and chromatin remodeling activity is wellservation that detachment or rounding of cells for a brief
period caused the reversible dissociation of the SYT/ established.
However, p300/CBP complexes also have nontran-p300 complex (Figure 4).
Until now, there has been little evidence pointing to an scription control functions. For example, they serve as
a platform for certain cyclin-dependent kinases (Gilesactive, dynamic role for ongoing nucleus-to-cytoplasm
signaling as the source of proper adhesion maintenance. et al., 1998) and participate in the regulated degradation
of p53 (Grossman et al., 1998). Therefore, in addition toThe data presented here suggest that for at least some
established cell lines and primary embryonic cells intro- a transcriptional control route, other possibilities remain
for SYT/p300 complexes to control adhesive activity,duced into culture immediately before their analysis,
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plated at 10%–20% density in the presence of 1 mM hydroxyureaincluding the controlled degradation, modification, and/
(Sigma). The following day, the hydroxyurea-containing medium wasor trafficking of certain specific target proteins, or an as
replaced with fresh medium containing 100 ng/ml nocodazoleyet undiscovered mechanism.
(Sigma). Cells were collected for analysis at the times indicated in theIndeed, events linking initial matrix contact to SYT/
text. An aliquot of each cell population was saved for fluorescence-p300 complex formation appear to be transcription acti-
activated cell sorting (FACS) analysis. For immunoprecipitation,
vation–independent, because actinomycin D treatment cells were lysed in NETN buffer (20 mM Tris [pH 8.0], 170 mM
had no effect on the formation of the p300/SYT com- NaCl, and 0.5% Nonidet P-40) containing protease and phosphatase
plexes as cells respread. A further interpretation of this inhibitors (4 mM sodium fluoride, 10 mg/ml aprotinin, 10 mg/ml leu-
result is that the events connecting SYT/p300 com- peptin, 10 mg/ml PMSF, 0.1 mM sodium orthovanadate, and 10 mg/
plexes to adhesion control are transcription activation– ml glycerol phosphate). After a 1- to 2-hr incubation with the first
independent. One cannot, however, rule out the possibil- antibody, an anti-mouse rabbit second antibody was added together
with protein A–Sepharose beads for 1 hr, followed by four washesity that SYT/p300 complexes operate as transcriptional
in high salt NETN (250 mM NaCl). IPs were boiled in an equal volumerepressor elements in mediating cell adhesion.
of Laemmli sample buffer and analyzed by SDS-PAGE. For in vivoResults presented in this article show that when cells
labeling, cells were incubated for 3 hr in 4 ml of methionine-freebecome confluent, SYT becomes tyrosine-phosphory-
DMEM containing 1 mCi of [35S]methionine and 5% dialyzed FBS.lated and interacts with two, heretofore undetected, ty-
Drugs were added as indicated. For reprecipitation experiments,rosine-phosphorylated proteins. Indeed, SYT contains
immune complexes were boiled in 100 ml of 50 mM Tris (pH 7.5),three motifs that individually or together could license
1% SDS, and 5 mM DTT, diluted 10-fold in NETN buffer, and repre-
specific interactions with the SH2 domains of tyrosine- cipitated with the indicated antibody.
phosphorylated proteins and thereby participate in tyro- Partial chymotrypsin and V8 protease digests were performed as
sine phosphorylation–mediated signaling events, one of follows. The excised 35S-labeled protein band was inserted in a
which is the control of cell adhesion. sample slot of a 15% SDS–polyacrylamide gel together with 60 ml
It was also shown that two SYT DN mutants that inter- of buffer (0.1% SDS, 1 mM EDTA, 2.5 mM DTT, and 0.125 M Tris
fered with cell adhesion failed to affect the expression [pH 6.8]) containing the indicated quantity of the relevant enzyme.
Electrophoresis was allowed to proceed to the stacking gel/runninglevels or tyrosine phosphorylation status of b1 integrin
gel interface, at which point the current was stopped for 30 minreceptor and certain key components of focal adhe-
to allow protease digestion to occur. Then, electrophoresis wassion complexes (paxillin, focal adhesion kinase, and
reinitiated.p130cas). Rather, they induced a defect in b1 integrin
For actinomycin D treatment experiments, confluent G1 CV-1 cellsfunction per se, as reflected by its specific failure to
were exposed to 5 mg/ml actinomycin D for 3 hr.assume an active conformation in cells transfected with
these mutants. Therefore, it seems likely that a major
outcome of SYT/p300 complex formation and function Purification of p50
is licensing of proper b1 integrin action after cellular p300/CBP mAb (AC240)-containing tissue culture supernatant (200
exposure to a fibronectin matrix. Given this result and ml) was chemically cross-linked to protein A–Sepharose with DMP,
the key role played by b1 integrin in matrix adhesion, following standard procedures (Harlow and Lane, 1988). Lysate from
one could argue that induction of full b1 activation is an 2 3 109 confluent CV-1 cells was immunoprecipitated with bead
cross-linked AC240, as described above. After boiling the beads inoutcome of SYT/p300 complex formation and that this
20 mM Tris (pH 6.8) and 0.5% SDS, the components of the noweffect is central to normal cell adhesion activity.
eluted p300/CBP immune complex were concentrated, resus-In a rare but typically aggressive human tumor, syno-
pended in distilled water, lyophilized, and then resuspended invial sarcoma, one copy of the SYT gene (on chromosome
Laemmli sample buffer for subsequent PAGE. The ensuing gel18) is typically translocated to an SSX gene on the X to
lane(s) was copper-stained, and p50 was excised for micro-form an SYT-SSX fusion gene (Clark et al., 1994). In most
sequencing.cases, all but the eight C-terminal residues of SYT are
fused to the 78 C-terminal residues of the SSX polypep-
tide. Interestingly, synovial sarcoma freely metastasizes Cloning of SYT and Construction of Wild-Type and Mutant
and invades, a property that can be viewed as depen- SYT Expression Vectors, and In Vitro SYT/p300
dent in part on alterations in normal adhesion-mediated Binding Assays
Using a lZap cDNA human library derived from 293 cells (a gift fromcellular behavior.
William Kealin), a 1.2-kb DNA fragment encoding full-length SYTIn this regard, our preliminary findings suggest that
cDNA was obtained as a PCR product using the 59 primer JE-1,SYT-SSX can interact effectively with p300 and serve
59-GCGCCCCGGGAATGTCTGTGGCTTTCGCGGCC-39, and the 39as a dominant negative affector of cell adhesion, much
primer JE-22, 59-GCGCGAATTCTCACTGCTGGTAATTTCCATACTGlike the two C-terminal mutants of SYT reported here
TCC-39.(J. E. E. and D. M. L., unpublished data). Of additional
All SYT mutants described in the text were created by PCR usinginterest is the fact that mere elimination of the same
primers specific for the relevant regions of the SYT cDNA insertedeight C-terminal residues (one of the three SH2-inter- in frame between the SmaI and EcoRI sites of PGEX-2T (Pharmacia).
acting motifs) lost during the formation of SYT-SSX in For the C-terminal deletion mutants SYT28, SYT29, and SYT30, 59
tumor cells led to the development of dominant negative primer JE-1 was used with primers JE-28, 59-GCGCGAATTCTCACT
SYT behavior in the adhesion assays reported here. This GGTCATATCCATAAGGCC-39; JE-29, 59-GCGCGAATTCTCACCTT
result leads to speculation that part of the function of GCTGCCCTGGGTAC-39; and JE-30, 59-GCGCGAATTCTCAATCTG
the SYT-SSX fusion protein is a product of loss of the TCTCTGACCCATC-39, respectively. For the N-terminal deletion mu-
tants, SYT33, SYT34, and SYT35, JE-22 as 39 primer was usedextreme SYT C terminus per se, leading to a breakdown
with JE-45, 59-GCGCCCCGGGAATGACCTCAGAGTGTTCTCAG-39;in the p300/SYT-dependent maintenance of adhesion
JE-46, 59-GCGCCCCGGGAATGCCTATGGGTCCTGGA-39; and JE-function.
35, 59-GCGCCCCGGGAATGTCAAGTAGCCATGGATCC-39, respec-
tively. The double mutant SYT35/29 was obtained using primers JE-Experimental Procedures
35 and JE-29.
SYT and all mutant derivatives were expressed as HA-taggedCell Lysis, Cell Synchronization, Immunoprecipitation, Limited
proteins. HA-tagged expression vectors were constructed first byProtease Digestion, and Actinomycin D Treatment
cutting individual PCR products, described above, with SmaI andCV-1 is a line of monkey kidney cells; IMR90 are primary, diploid
human fibroblasts. For synchronization, actively growing cells were EcoRI. After exposure to T4 polynucleotide kinase, each product
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and a DNA fragment encoding an HA epitope tag (obtained by an- min at 378C. After two washes with serum-free DME, embryonic
cells were ready for analysis in the adhesion assay, described above.nealing the 59 primer JE-23, 59-AGCTTACCATGGCCTACCCCTAC
GACGTGCCCGACTACGCCTCCCTCCC-39, to the 39 primer JE-24,
59-GGGAGGGAGGCGTAGTCGGGCACGTCGTAGGGGTAGGCCAT b1 Integrin Activation Assay
GGTA-39) were ligated between the HindIII and the EcoRI sites of The b1 integrin assay was performed as previously described (Baz-
the expression vector pcDNA3 (Invitrogen), which contains a rabbit zoni et al., 1995) with certain modifications. CV-1 cells were trans-
b-globin intron to optimize expression (Scully et al., 1997). fected with various HA-tagged SYT species (30 mg) and, in some
For in vitro translation experiments, SYT was inserted alone into cases, with a CD19 expression vector (z4 mg), using Superfect
pcDNA3 between a blunt-ended (with Klenow fragment and dNTPs) (Qiagen). When CD19 was co-expressed, transfectants were purified
HindIII site and its EcoRI site. In vitro–translated SYT was assayed on CD19 beads (Dynal). At 48 hr after plating in complete medium,
for binding to the various GST fusion proteins (Lee et al., 1995), as they were detached by brief trypsinization, allowed to recover in
previously described (Grossman et al., 1998). complete medium, and washed once with PBS and once with TBS
buffer (24 mM Tris-HCl [pH 7.4], 137 mM NaCl, and 2.7 mM KCl).
Immunofluorescence The cells were then incubated for 30 min at 378C in TBS buffer
The affinity-purified, SYT-specific polyclonal antibody B24 and the containing 5% BSA and 0.02% sodium azide, with or without 2 mM
preimmune serum (from the rabbit that generated B24) were used MnCl2. This was followed by incubation on ice for 45 min in the
at a 1:200 dilution. HA-specific mAb (12CA5) was used at a 1:15 presence of 2 mg/ml 9EG7 antibody (anti b1; Pharmingen). After
dilution. Immunofluorescent analysis of endogenous and trans- three washes with TBS with 1% BSA, a rhodamine-labeled second
fected SYT was performed as previously described (Grossman et anti-mouse Ig antibody (Jackson Laboratories) was added at 1:200
al., 1998). Rhodamine phalloidin staining was performed, following on ice for 45 min, followed by three washes with TBS. Binding of
the manufacturer’s instructions (Molecular Probes). 9EG7 to the b1 integrin activation epitope on transfected cells was
visualized after they were allowed to adhere to poly-L-lysine-coated
cover slips for 30 to 0 min, followed by fixation and staining withCell Detachment
fluorescein-conjugated anti-HA antibodies, as described above.For detachment with EDTA, confluent/quiescent CV-1 cells were
Both wild-type and mutant SYT transfectants adhered with highwashed twice with HCMF buffer (8 g/l NaCl, 0.4 g/l KCl, 0.09 g/l
efficiency (.90%) to poly-L-lysine surfaces. After scoring the cellsNa2HPO4, 1.0 g/l glucose, and 2.4 g/l HEPES in 0.005 M NaOH [pH
for both b1 fluorescence and HA-SYT expression, the percentage7.4]) and detached by a 5-min incubation in PBS and 0.02% EDTA.
of transfected cells that were both red and green was recorded.Detached cells were washed once with HCMF and then washed in
serum-free growth medium. They were then taken up in serum-
containing growth medium and, after rotating on a wheel at 378C Acknowledgments
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